{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:20:36Z","timestamp":1792243236424,"version":"4.4.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Real-world data comparing dupilumab vs. Janus kinase (JAK)1 inhibitors for refractory prurigo nodularis (PN) are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare the effectiveness and safety of dupilumab, abrocitinib and upadacitinib in refractory PN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study of adults with refractory prurigo nodularis (PN). This was defined as no response to at least two systemic therapies, Peak Pruritus Numerical Rating Scale (PP-NRS) \u2265 7 and at least 20 nodules. Patients received dupilumab 300\u202fmg every 2 weeks (n = 12), abrocitinib 200\u202fmg daily (n = 8) or upadacitinib 30\u202fmg daily (two doses of 15\u202fmg, n = 8). Follow-up assessments were conducted at weeks 12 (n = 28), 24 (n = 22) and 36 (n = 15). Primary outcomes were changes in PP-NRS and nodule count. Secondary outcomes included changes in Dermatology Life Quality Index (DLQI), Hospital Anxiety and Depression Scale (HADS) and Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9) scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients receiving dupilumab were older and had a longer disease duration and higher IgE levels (all P \u2264 0.002). By month 6, a \u2265 4-point reduction in PP-NRS was achieved by 56% of patients on dupilumab, 86% on abrocitinib and 100% on upadacitinib. Nodule reduction by \u2265 50% was seen in 11%, 100% and 100%, respectively. DLQI \u2265 9-point improvement was seen in 33%, 86% and 83%, respectively. HADS scores decreased in all groups, mostly so with upadacitinib. Adverse events included acne (n = 4), creatinine kinase elevation (n = 3), injection-site reaction (n = 2) and herpes zoster (n = 2). No cases of major adverse cardiovascular events, venous thromboembolism, malignancy, serious infection, death or discontinuation occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a small, imbalanced multicentre cohort, JAK1 inhibitors showed faster itch relief and greater lesion clearance signals than dupilumab, with meaningful improvements in quality of life.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llaf518","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T13:09:10Z","timestamp":1763644150000},"page":"587-595","source":"Crossref","is-referenced-by-count":3,"title":["Comparative effectiveness and safety of upadacitinib, abrocitinib and dupilumab in treatment-resistant prurigo nodularis"],"prefix":"10.1093","volume":"51","author":[{"given":"Abdullah","family":"Demirbas","sequence":"first","affiliation":[{"name":"Kocaeli University Faculty of Medicine, Department of Dermatology , Kocaeli ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esin","family":"Diremsizoglu","sequence":"additional","affiliation":[{"name":"Kocaeli University Faculty of Medicine, Department of Dermatology , Kocaeli ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Esen","sequence":"additional","affiliation":[{"name":"Dicle University Faculty of Medicine, Department of Dermatology , Diyarbak\u0131r ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gozde","family":"Ulutas Demirbas","sequence":"additional","affiliation":[{"name":"Kocaeli City Hospital, Department of Dermatology , Kocaeli ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"2026032611521677400_llaf518-B1","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/bjd\/ljae052","article-title":"Prurigo nodularis: new insights into pathogenesis and novel therapeutics","volume":"190","author":"Liao","year":"2024","journal-title":"Br J Dermatol"},{"key":"2026032611521677400_llaf518-B2","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.5826\/dpc.1502a4716","article-title":"Epidemiology and severity of prurigo nodularis in Europe: a literature review with an application to Italian data","volume":"15","author":"Patruno","year":"2025","journal-title":"Dermatol Pract Concept"},{"key":"2026032611521677400_llaf518-B3","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1016\/j.jaip.2020.05.051","article-title":"Prevalence of prurigo nodularis in the United States","volume":"8","author":"Whang","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026032611521677400_llaf518-B4","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s13555-025-01437-8","article-title":"Emerging therapies in the treatment of prurigo nodularis: biological therapy and systematic review of literature","volume":"15","author":"Licata","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026032611521677400_llaf518-B5","doi-asserted-by":"crossref","first-page":"5164","DOI":"10.3390\/ijms25105164","article-title":"Prurigo nodularis: pathogenesis and the horizon of potential therapeutics","volume":"25","author":"Yook","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026032611521677400_llaf518-B6","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4103\/ds.DS-D-24-00100","article-title":"Recent advances in treatment of prurigo nodularis","volume":"42","author":"Chen","year":"2024","journal-title":"Dermatol Sin"},{"key":"2026032611521677400_llaf518-B7","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.clindermatol.2025.03.010","article-title":"The big four in the pathogenesis and pathophysiology of prurigo nodularis: interplay among type 2 inflammation, epidermal hyperplasia, dermal fibrosis, and itch from neuroimmune dysregulation","volume":"43","author":"Hashimoto","year":"2025","journal-title":"Clin Dermatol"},{"key":"2026032611521677400_llaf518-B8","doi-asserted-by":"crossref","first-page":"8098","DOI":"10.1038\/s41598-024-58013-x","article-title":"Comprehensive plasma cytokine and chemokine profiling in prurigo nodularis reveals endotypes in type 2 inflammation","volume":"14","author":"Cornman","year":"2024","journal-title":"Sci Rep"},{"key":"2026032611521677400_llaf518-B9","doi-asserted-by":"crossref","first-page":"e1390","DOI":"10.1002\/cti2.1390","article-title":"Molecular and cellular mechanisms of itch and pain in atopic dermatitis and implications for novel therapeutics","volume":"11","author":"Kwatra","year":"2022","journal-title":"Clin Transl Immunol"},{"key":"2026032611521677400_llaf518-B10","doi-asserted-by":"crossref","first-page":"113433","DOI":"10.1016\/j.celrep.2023.113433","article-title":"Sensory neuronal STAT3 is critical for IL-31 receptor expression and inflammatory itch","volume":"42","author":"Takahashi","year":"2023","journal-title":"Cell Rep"},{"key":"2026032611521677400_llaf518-B11","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jaci.2023.07.005","article-title":"Single-cell profiling of prurigo nodularis demonstrates immune\u2013stromal crosstalk driving profibrotic responses and reversal with nemolizumab","volume":"153","author":"Ma","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"2026032611521677400_llaf518-B12","doi-asserted-by":"crossref","first-page":"1301817","DOI":"10.3389\/fimmu.2023.1301817","article-title":"Molecular mechanisms of pruritus in prurigo nodularis","volume":"14","author":"Shao","year":"2023","journal-title":"Front Immunol"},{"key":"2026032611521677400_llaf518-B13","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","article-title":"Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials","volume":"29","author":"Yosipovitch","year":"2023","journal-title":"Nat Med"},{"key":"2026032611521677400_llaf518-B14","doi-asserted-by":"crossref","first-page":"878","DOI":"10.3390\/jcm13030878","article-title":"Dupilumab for treatment of prurigo nodularis: real-life effectiveness for up to 84 weeks","volume":"13","author":"Paganini","year":"2024","journal-title":"J Clin Med"},{"key":"2026032611521677400_llaf518-B15","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1001\/jamadermatol.2024.1464","article-title":"Efficacy and safety of abrocitinib in prurigo nodularis and chronic pruritus of unknown origin: a nonrandomized controlled trial","volume":"160","author":"Kwatra","year":"2024","journal-title":"JAMA Dermatol"},{"key":"2026032611521677400_llaf518-B16","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3390\/medicina61040631","article-title":"New and emerging biologics and Jak inhibitors for the treatment of prurigo nodularis: a narrative review","volume":"61","author":"Bianco","year":"2025","journal-title":"Medicina (Kaunas)"},{"key":"2026032611521677400_llaf518-B17","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jaad.2024.06.094","article-title":"Effective response to upadacitinib in patients affected by prurigo nodularis and by atopic dermatitis with a predominant prurigo nodularis pattern: a multicenter case series study","volume":"91","author":"Pezzolo","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2026032611521677400_llaf518-B18","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00403-025-04071-8","article-title":"Abrocitinib as a novel therapeutic approach for refractory prurigo nodularis: real-world evidence","volume":"317","author":"Demirbas","year":"2025","journal-title":"Arch Dermatol Res"},{"key":"2026032611521677400_llaf518-B19","first-page":"2715","article-title":"Evaluation of the effects of IL-22 on the proliferation and differentiation of keratinocytes in vitro","volume":"22","author":"Zhuang","year":"2020","journal-title":"Mol Med Rep"},{"key":"2026032611521677400_llaf518-B20","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.3390\/cells13161398","article-title":"IL-22 in atopic dermatitis","volume":"13","author":"Laska","year":"2024","journal-title":"Cells"},{"key":"2026032611521677400_llaf518-B21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jaci.2025.02.029","article-title":"Endotypes of atopic dermatitis","volume":"156","author":"Fyhrquist","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"2026032611521677400_llaf518-B22","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1001\/jamadermatol.2023.3251","article-title":"Patient perspectives on living with severe prurigo nodularis","volume":"159","author":"Rodriguez","year":"2023","journal-title":"JAMA Dermatol"},{"key":"2026032611521677400_llaf518-B23","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1007\/s12325-025-03217-4","article-title":"Prurigo Nodularis PaTient-Reported BurdEn of SicKness (PN TREK): a cross-sectional survey of patient-reported burden of disease in patients with PN from the US","volume":"42","author":"Kwatra","year":"2025","journal-title":"Adv Ther"},{"key":"2026032611521677400_llaf518-B24","first-page":"53","article-title":"Psychiatric comorbidity in prurigo nodularis and the impact of socioeconomic status","volume":"15","author":"Han","year":"2022","journal-title":"J Clin Aesthet Dermatol"},{"key":"2026032611521677400_llaf518-B25","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4168\/aair.2024.16.5.546","article-title":"Treatment with upadacitinib in refractory prurigo nodularis: a prospective cohort study","volume":"16","author":"Lee","year":"2024","journal-title":"Allergy Asthma Immunol Res"},{"key":"2026032611521677400_llaf518-B26","doi-asserted-by":"crossref","first-page":"248","DOI":"10.5114\/ada.2025.152080","article-title":"Dupilumab treatment for prurigo nodularis: a retrospective study of 76 patients","volume":"42","author":"Zhao","year":"2025","journal-title":"Postepy Dermatol Alergol"},{"key":"2026032611521677400_llaf518-B27","doi-asserted-by":"crossref","first-page":"e892","DOI":"10.1111\/jdv.19980","article-title":"Long-term therapeutic response to dupilumab in patients affected by prurigo nodularis: a real-world retrospective study","volume":"38","author":"Chiricozzi","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026032611521677400_llaf518-B28","doi-asserted-by":"crossref","first-page":"103336","DOI":"10.1016\/j.annder.2024.103336","article-title":"Efficacy of dupilumab in chronic prurigo: a multicentre retrospective study","volume":"152","author":"Gael","year":"2025","journal-title":"Ann Dermatol Venereol"},{"key":"2026032611521677400_llaf518-B29","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.3390\/jcm14092953","article-title":"Real-world effectiveness and safety of upadacitinib and abrocitinib in moderate-to-severe atopic dermatitis: a 52-week retrospective study","volume":"14","author":"Ibba","year":"2025","journal-title":"J Clin Med"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf518\/65453004\/llaf518.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/4\/587\/65453004\/llaf518.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/4\/587\/65453004\/llaf518.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T15:52:25Z","timestamp":1774540345000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/4\/587\/8339955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":29,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,11,21]]},"published-print":{"date-parts":[[2026,3,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf518","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2025,11,21]]}}}